GLG News by Physicians who Treat Depression (US)

The notion that Lilly is promulgating here by marketing Cialis as a daily preparation is that you can have it both ways, namely always being prepared for sexual relations that are spontaneous.  From an observer of the human comedy (me), this will sell very well as the Baby Boom ages.  No mention...

Pfizer Inc (NYSE:PFE) and Taisho Pharmaceutical Co., Ltd. (OTC:TSOPF.PK) announced the signing of a definitive agreement for worldwide collaboration to research, develop and commercialize TS-032.   TS-032 is a metabotropic glutamate receptor (mGluR) agonist, a novel drug candidate for the...

Allosteric modulation of the metabotropic glutamate receptor 5 (mGluR5) for treatment of schizophrenia seems highly promising from a basic science perspective.  It has not been well tested in the clinic yet.  The fact that two major pharmaceutical firms are now in the hunt towards clinical...

Addex Pharmaceuticals (Swiss:ADXN.SW) announced on January 3, 2008 an exclusive worldwide license agreement with Merck & Co., Inc. (NYSE:MRK) to develop ADX63365, a potent and selective positive allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5) with potential for the...

An interesting observation made as a consequence of the widespread use of serotonin specific reuptake inhibitors (SSRI) in clinical psychiatry is that these medications tend to affect appetite.  SSRIs can cause either weight gain or loss.  There was a time when they were extensively used in...

Lu AA21004 is a new "bis-aryl-sulphanyl modulator" that has both preclinical and clinical support for future development for market as an "affective modulator". (I use the term affective modulator because I doubt whether the ultimate indication for this agent will be based on anxiety or depression.) ...

Cymbalta (Eli Lilly: LLY) solidifies its place in the depression marketplace with this new FDA approval for maintenance treatment.  The incrementaL impact on sales is another matter.

1. The results of this study demonstrtae a treatment in development, PRX-03140, which may provide stronger pro-cognitive effects than those currently available for Alzheimer's disease. 2. PRX-03140 may be a disease altering alternative to other treatments currently in development. 3. The mechanism...

Helping regenerate or preventing death of dopaminergic neurons in the motor system is novel and exciting.  That is the strategy described in the accomapanying clinical trial of insertion of a nerve growth factor gene into the putamen of patients with Parkinson’s disease—a region of the brain affected...

Here we go again; look at all metabolites of a successful drug for efficacy to increase your bang for the corporate buck.  Brilliant--because success is virtually assured at relatively little cost.  Venlafaxine is a reasonably good antidepressant, and in my experience, useful except in...